Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0A5RD
|
|||
Former ID |
DCL000947
|
|||
Drug Name |
Radafaxine
|
|||
Synonyms |
Hydroxybupropion
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Major depressive disorder [ICD-11: 6A70.3; ICD-10: F32.2] | Discontinued in Phase 2 | [1] | |
Company |
GlaxoSmithKline
|
|||
Structure |
Download2D MOL |
|||
Formula |
C13H18ClNO2
|
|||
Canonical SMILES |
CC1C(OCC(N1)(C)C)(C2=CC(=CC=C2)Cl)O
|
|||
InChI |
1S/C13H18ClNO2/c1-9-13(16,17-8-12(2,3)15-9)10-5-4-6-11(14)7-10/h4-7,9,15-16H,8H2,1-3H3/t9-,13+/m0/s1
|
|||
InChIKey |
RCOBKSKAZMVBHT-TVQRCGJNSA-N
|
|||
CAS Number |
CAS 192374-14-4
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Dopamine transporter (DAT) | Target Info | Inhibitor | [1], [2] |
Norepinephrine transporter (NET) | Target Info | Inhibitor | [1], [2] | |
KEGG Pathway | Dopaminergic synapse | |||
Parkinson's disease | ||||
Cocaine addiction | ||||
Amphetamine addiction | ||||
Alcoholism | ||||
Panther Pathway | Adrenaline and noradrenaline biosynthesis | |||
Parkinson disease | ||||
Dopamine receptor mediated signaling pathway | ||||
Pathway Interaction Database | Alpha-synuclein signaling | |||
Reactome | Na+/Cl- dependent neurotransmitter transporters | |||
WikiPathways | Monoamine Transport | |||
NRF2 pathway | ||||
Dopaminergic Neurogenesis | ||||
Parkinsons Disease Pathway | ||||
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
Neurotransmitter Clearance In The Synaptic Cleft |
References | Top | |||
---|---|---|---|---|
REF 1 | Emerging drugs for bipolar disorder. Expert Opin Emerg Drugs. 2006 Nov;11(4):621-34. | |||
REF 2 | Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.